We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
34. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
35. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
36. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
37. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
38. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
39. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
40. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
41. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
42. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
43. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
45. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
46. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
47. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
48. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
49. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
50. Cow’s milk allergy: the future
- Dr. Carina Venter
-
51. Cow's milk allergy: management
- Dr. Carina Venter
-
52. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
53. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
54. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
55. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
56. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
57. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
58. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
59. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
60. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
61. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
63. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
64. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
65. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
66. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
67. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
68. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
69. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
70. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
71. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
72. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
73. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
74. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
75. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
76. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
77. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
78. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
79. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
80. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
81. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
82. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
83. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
84. AI and big data in drug discovery
- Mr. Ed Addison
-
85. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
86. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
87. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
88. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
89. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
90. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
91. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
92. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
93. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
94. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
95. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
96. New drugs for asthma
- Prof. Peter Barnes
-
97. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
98. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- The effects of stillbirth
- Best practice in maternity care
- Optimal clinical care after stillbirth
- Available clinical guidance
- Available clinical evidence
- Stillbirth in high resource settings (1)
- Stillbirth in high resource settings (2)
- Listening to Parents report (1)
- Listening to Parents report (2)
- Descriptive studies identify good care (1)
- Descriptive studies identify good care (2)
- Process of diagnosis and early care
- Diagnosis: language
- After a diagnosis is made
- Information giving
- Mode of delivery
- The time between diagnosis and birth
- Why have investigations after perinatal death?
- Value of investigations after perinatal death
- Why do parents have investigations after stillbirth?
- Parental decision making about PM
- Barriers to consent for autopsy (1)
- Barriers to consent for autopsy (2)
- Seeing and holding baby (1)
- Seeing and holding baby (2)
- Perinatal bereavement service
- Common experiences of parents
- Developing a regional guideline
- Impact of regional guideline (1)
- Impact of regional guideline (2)
- Specialist bereavement care after preeclampsia
- Parents’ experience: perinatal death & hypertension
- Unclear diagnosis & lack of control
- Impact on key grief activities
- Lactation suppression
- Need for aftercare
- Summary
- What can we do to improve care?
- Narrative-based medicine
- Evaluating stillbirth stories
- Impact on clinicians
- Listening to the archive changed views on stillbirth
- Conclusions
- Acknowledgements
Topics Covered
- Stillbirth diagnosis, investigation and aftercare
- Best practice in maternity care
- Clinical guidelines
- Preeclampsia
- Diagnosis of intrauterine fetal death
- Investigations following perinatal death
- Postmortem
- Barriers to consent for autopsy
- Bereavement care
- Lactation suppression
- Narrative-based medicine and stillbirth stories
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Heazell, A.E.P. (2024, March 31). Stillbirth: diagnosis, investigation and aftercare [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/FXNM4774.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
A selection of talks on Gynaecology & Obstetrics
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Alex Heazell.
I'm a professor of obstetrics at
the Tommy's Stillbirth
Research Center
of the University of Manchester.
I'm going to talk to you
today about stillbirth,
aspects about the diagnosis,
investigation, and after care.
0:17
It's important that we
think about stillbirth
because the effects of
stillbirth affect mothers,
their families, health services,
society and government.
Women bear the brunt of
the emotional and
psychological distress
and can become very isolated.
It was estimated in
2016 that there are
about 2.6 million
stilbirths per year.
The current WHO estimate
is there are about
1.9 million stillbirths
per year globally.
We know that women
who experience
stillbirth have an increased
risk of family breakdown.
There's also a great
deal of stigma.
Women can even be abandoned as
a result of pregnancy
loss or abused.
We know that those of us
working in healthcare,
that this pregnancy
loss is associated with
increased healthcare
costs and also a
negative effect on staff.
Also for those in government,
that there is reduced
earnings from employment,
maternity and paternity leave,
and also that in
some countries the government
meets the healthcare expenses.
So the effect of
stillbirth is not simply
about
the emotional and psychological
distress on the mother,
but it radiates out
to affect us all.
1:29
I've paraphrased a well known
saying that any society
and nation is judged on
the basis of how it treats
its weakest members and
I would argue that our
maternity service should be
judged on how it treats
its most vulnerable clients
and how we look after
parents who have experienced
a stillbirth I think is
a good barometer for the quality
of care we offer people,
all the people
using our service.
Back in 2012,
I in collaboration
with Soo Downe,
who's a professor of midwifery,
we looked at parents experiences
of stillbirth in UK hospitals.
This shows many
commonalities with
themes from other very
similar studies globally.
But one thing that came out of
this study is how
enduring the effects are.
So things could
either be really bad.
Here someone describes how
their delivery was awful
from beginning to end.
They treated me like the
woman with the dead baby.
There was no sympathy.
When I asked to see a doctor,
this particular doctor came
in and said, we are very busy.
His exact words, I'll never
forget them Well,
with all due respect,
your baby's dead already,
which was just the most
awful thing you could say.
Then that goes through to
actually a very
positive experience of
still being able to connect
with their baby and
a sense that there was still
a sense of motherhood there.
So the midwife made me
feel incredibly proud.
A natural reaction after
just giving birth is
reliving the birth
and wanting to
talk about the birth experience.
It sounds odd, but because
I'd had such a good birth,
I felt I could behave
like a normal mother.
I could talk about
that experience
as a normal labor
to close family.
That was really important
to acknowledge Zoe,
her stillborn baby, in a way.